We acknowledge that a major limitation in the present study is the lack of functional analysis of the receptors in our model of RP; however, our results support the notion that pharmacological modulation of purinergic receptors could be of clinical therapeutic utility also in inherited retinal neurodegenerative diseases, as has been proposed in several other pathologies, and we consider the role of these receptors worthy of further study [2,41,44]. This evidence concerns the gene P2RX4 and retinitis pigmentosa 1.